Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

atnahs pharma netherlands b.v., amsterdam array - 4442 atenolol; 335 chlortalidon - potahovaná tableta - 100mg/25mg - atenolol a thiazidy

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

atnahs pharma netherlands b.v., amsterdam array - 4442 atenolol - potahovaná tableta - 100mg - atenolol

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

atnahs pharma netherlands b.v., amsterdam array - 4442 atenolol - potahovaná tableta - 50mg - atenolol

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

the simple pharma company limited, dublin array - 1422 testosteron - transdermální gel - 20mg/g - testosteron

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

curium netherlands b.v., petten array - 9673 chlorid thallnÝ-(201tl) - injekční roztok - 37mbq/ml - chlorid thallnÝ-(201tl)

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - cytostatika - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infekce dýchacích syncyciálních virů - vakcíny - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. použití této vakcíny musí být v souladu s oficiálními doporučeními.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukemie, myeloid - antineoplastická činidla - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycythemia vera - imunostimulancia, - besremi je indikován jako monoterapie u dospělých pro léčbu po polycytemii vera bez symptomatická splenomegalie.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anémie, kosáčková buňka - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.